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Dendritic cells (DCs) in tissues and lymphoid organs
comprise distinct functional subsets that differen-
tiate in situ from circulating progenitors. Tissue-
specific signals that regulate DC subset differ-
entiation are poorly understood. We report that
DC-specific deletion of the Notch2 receptor caused
a reduction of DC populations in the spleen. Within
the splenic CD11b+ DC subset, Notch signaling
blockade ablated a distinct population marked by
high expression of the adhesion molecule Esam.
The Notch-dependent Esamhi DC subset required
lymphotoxin beta receptor signaling, proliferated
in situ, and facilitated CD4+ T cell priming. The
Notch-independent Esamlo DCs expressed mono-
cyte-related genes and showed superior cytokine
responses. In addition, Notch2 deletion led to the
loss of CD11b+CD103+ DCs in the intestinal lamina
propria and to a corresponding decrease of IL-17-
producing CD4+ T cells in the intestine. Thus, Notch2
is a common differentiation signal for T cell-priming
CD11b+ DC subsets in the spleen and intestine.
INTRODUCTION
Dendritic cells (DCs) represent the primary antigen (Ag)-present-
ing cell population in the immune system. They can detect
pathogens through pattern recognition receptors such as Toll-
like receptors (TLRs), migrate into the T cell areas of lymphoid
organs, secrete immunostimulatory cytokines such as inter-
leukin-12 (IL-12), and present pathogen-derived peptides to
naive T cells (Steinman and Idoyaga, 2010). To initiate appro-
priate immune responses to different pathogen types, DCs
comprise distinct functional subsets including interferon-pro-
ducing plasmacytoid DCs (pDCs) and two main subsets of clas-
sical DCs (cDCs). The CD8a-expressing CD8+CD11b DCs in780 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.lymphoid organs and their CD103+CD11b counterparts in
tissues mediate efficient cross-presentation to cytotoxic T cells
(Shortman and Heath, 2010). The CD8a-negative CD8CD11b+
subset is preferentially involved in MHC class II (MHC II)-
restricted Ag presentation to CD4+ helper T cells (Dudziak
et al., 2007). In the spleen, CD11b+ DCs are preferentially local-
ized to the marginal zone (MZ), a unique structure that filters the
incoming blood (Mebius and Kraal, 2005). In the intestinal lamina
propria (LP), the CD11b+ DC population is comprised of two
distinct subsets. The CD11b+CD103+ subset is thought to
mediate Ag capture and transport to mesenteric lymph node
(LN). Recently, it was shown to be particularly efficient for the
induction of interleukin 17 (IL-17)-secreting helper T (Th17) cells
in vitro (Denning et al., 2011), although its role in T cell differenti-
ation in vivo remains unclear. Conversely, the CD11b+CD103
population does not migrate to LN, is capable of high-level cyto-
kine secretion, and appears closely related to macrophages
(Bogunovic et al., 2009; Schulz et al., 2009; Varol et al., 2009).
Classical DCs along with pDCs, monocytes, and macro-
phages originate from the common macrophage and DC
progenitor (MDP) in the bone marrow (BM) (Fogg et al., 2006).
Commitment to the DC lineage occurs in the BM at the level of
common DC progenitors (CDP) (Naik et al., 2007; Onai et al.,
2007), whereas the terminal differentiation of classical DC
subsets occurs in the periphery. All DCs in the lymphoid organs
and CD103+ DCs in tissues are thought to develop from
pre-DC (Ginhoux et al., 2009; Liu et al., 2009), a blood-derived
progenitor originally defined in the spleen (Naik et al., 2006).
Similarly, the unique CD11b+CD103+ subset in the intestinal LP
is derived from pre-DCs. All pre-DC-derived subsets are low or
negative for fractalkine receptor Cx3cr1 and preferentially
depend on signaling by Flt3 ligand through its receptor Flt3.
On the other hand, CD11b+ DCs in tissues arise from MDP-
derived monocytes, express Cx3cr1, and depend on macro-
phage colony-stimulating factor receptor Csf1r rather than on
Flt3 (Bogunovic et al., 2009; Ginhoux et al., 2009; Varol et al.,
2009). Thus, the homogeneity and single pre-DC origin of
DC subsets in lymphoid organs appears to contrast with the
functional heterogeneity and dual origin of DC subsets in
tissues such as the intestine. Furthermore, little is known about
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tissue specificity on DC progenitors.
Notch is an evolutionarily conserved signaling pathway that
allows cells to adopt cell fates dictated by their microenviron-
ment (Bray, 2006). The interaction of Notch receptor with its
ligand on a neighboring cell causes receptor cleavage that
releases the intracellular domain of Notch (NICD), which translo-
cates into the nucleus and binds the transcription factor CSL
(called RBPJ in the mouse). The resulting NICD-RBPJ complex
recruits coactivators of the Mastermind (MAML) family and
activates Notch-dependent gene expression programs, includ-
ing canonical targets such as Hes1 and Deltex (Dtx1). Notch
signaling is regulated at multiple levels including ligand endocy-
tosis, receptor glycosylation, and composition of the transacti-
vation complex. Mammals have five Notch ligands of the
Delta-like and Jagged families and four Notch receptors
(Notch1–4), of which only Notch1 and Notch2 contain transacti-
vation domains. These two receptors appear to mediate the
majority of Notch-dependent developmental processes and
their deletion causes embryonic lethality.
Notch signaling plays essential roles in lymphocyte develop-
ment by inducing progenitor differentiation in unique anatomic
locations (Radtke et al., 2010; Yashiro-Ohtani et al., 2010;
Yuan et al., 2010). Thus, Delta-like 4 (Dll4) on thymic epithelium
drives T cell lineage development through Notch1 on thymic
progenitors, whereas Delta-like 1 (Dll1) on the splenic MZ
stroma specifies MZ B cell subset through Notch2. However,
the role of Notch in the development of innate immune
system remains poorly understood. Notch1 has been impli-
cated in DC differentiation in vitro (Cheng et al., 2003; Zhou
et al., 2009), although earlier studies on Notch1 deletion in vivo
argue against this notion (Radtke et al., 2000). We have shown
previously that DC-specific deletion of RBPJ caused partial
reduction of the splenic CD11b+ DCs, which express Notch
target Dtx1 in an RBPJ-dependent manner (Caton et al.,
2007). However, major questions remain concerning the Notch
receptor involved, the partial nature and functional conse-
quences of the phenotype, and the role of Notch in DC differen-
tiation in tissues.
We now report that the Notch2 receptor controls DC differen-
tiation in the spleen. Among the CD11b+ DCs, Notch2-RBPJ
signaling specifies a unique Cx3cr1loEsamhi DC subset, which
was required for efficient T cell priming in the spleen. Moreover,
Notch2 was necessary for the development of lamina propria
CD11b+CD103+ DCs, which in turn maintain optimal numbers
of Th17 cells. These results establish Notch2 signaling as an
essential tissue-specific determinant of DC differentiation in
the spleen and intestine. Furthermore, they demonstrate that
CD11b+ DCs both in tissues and in lymphoid organs are
heterogeneous and include a distinct Notch-dependent subset
specialized in T cell priming.
RESULTS
Notch2 Controls Splenic DC Differentiation
To determine the role of individual Notch receptors in DC differ-
entiation, we used Itgax-cre (CD11c-cre) deleter strain for DC-
specific deletion of conditional Notch1 (Radtke et al., 1999)
and Notch2 (McCright et al., 2006) alleles. As a complementaryIway to block canonical Notch signaling in DCs, we used Itgax-
cre-induced expression of dominant-negative human MAML1
(DNMAML1) protein fused to green fluorescent protein (GFP)
(Tu et al., 2005). The analysis of GFP fluorescence confirmed
DC-specific activation of DNMAML1 expression in the resulting
DC-DNMAML1 mice (see Figure S1 available online). Indeed,
Notch2-dependent MZ B cells showed minimal recombination
and were present in normal numbers in mice with Notch2 dele-
tion (DC-Notch2D) or with DNMAML1 activation (Figure S1). As
shown in Figures 1A and 1B, mice with DC-specific deletion of
Notch1 (DC-Notch1D) had normal splenic DC populations. This
is consistent with normal DC development after Notch1 deletion
in hematopoietic chimeras (Radtke et al., 2000). In contrast, DC-
Notch2D and DC-DNMAML1 mice had reduced fraction and
absolute numbers of splenic CD11chiMHC II+ classical DCs
(Figures 1A and 1B). The reduction was specific to cDCs, as
shown by the fact that pDC populationswere normal despite effi-
cient cre recombination (Figure S1).
As with DC-specific Rbpj deletion (DC-RbpjD) (Caton et al.,
2007), the CD8CD11b+ subset was significantly reduced in
the spleens of DC-Notch2D and DC-DNMAML1 mice (Figures
1C and 1D). In addition, the CD8+ DC subset was decreased
in DC-Notch2D spleens, whereas a distinct population of
CD8CD11b double-negative cells became apparent within
the DC population. A similar albeit less pronounced phenotype
was observed in DNMAML1-overexpressing DCs, suggesting
the involvement of canonical Notch signaling. The CD8CD11b
double-negative DCs arising after Notch2 deletion included two
distinct populations expressing either signal regulatory protein
alpha (SIRPa) or CD24, the markers associated with CD11b+
and CD8+ DC lineages, respectively (Figure 1E; Naik et al.,
2006). Similar populations could be detected among the rare
CD8CD11b DCs in wild-type mice, suggesting that they
represent natural immature stages of CD11b+ and CD8+ DC
development. Earlier developmental stages such as pre-DCs
were unaffected by Notch2 deletion (Figure S1), consistent
with a late differentiation defect.
In addition to the decrease in number, splenic CD11b+ DCs in
DC-Notch2D mice exhibited an abnormal surface phenotype
including higher CD11b and lower (albeit heterogeneous) SIRPa
expression (Figure 1F). Splenic CD11b+ DCs express the
specific marker Dcir2 (33D1) (Dudziak et al., 2007) and a fraction
of them express CD4 (Kamath et al., 2000). As shown in Fig-
ure 1F, the fraction of Dcir2+ and CD4+ cells was profoundly
reduced in Notch2-deficient CD11b+ DCs. Altogether, these
data demonstrate that Notch2 deletion impairs the development
of CD11b+ and CD8+ splenic DCs and causes phenotypic abnor-
mality of the residual CD11b+ DC population.
Notch2-RBPJ Signaling Specifies a Distinct Population
of Splenic CD8– DCs
To explain the partial reduction and abnormal phenotype of
CD11b+ DCs in DC-Notch2D, DC-DNMAML1, and DC-RbpjD
mice, we hypothesized that CD11b+ DCs are heterogeneous
and include a distinct population eliminated by Notch2-RBPJ
blockade. We therefore crossed DC-RbpjD mice to a Cx3cr1-
GFP reporter strain, which has been used to resolve DC subsets
in the spleen and tissues (Bar-On et al., 2010; Varol et al., 2009).
We found that CD11b+ DCs in wild-type spleens included GFPhimmunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc. 781
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Figure 1. Notch2 Signaling Regulates
Splenic DC Development
Mice with Itgax-cre-mediated deletion of Notch1
or Notch2 or DC-specific overexpression of
DNMAML1 were analyzed along with the respec-
tive cre-negative littermate controls. Statistically
significant differences are indicated as follows:
***p < 0.001; **p < 0.01; *p < 0.05.
(A) Representative staining profiles of total sple-
nocytes with the fraction of CD11chiMHC II+ DCs
indicated.
(B) The fraction (top) and absolute number
(bottom) of splenic DCs (mean ± SD of three to six
animals per group).
(C) Staining profiles of gated CD11chiMHC II+
splenic DCs, with CD11b+ (blue), CD8+ (green),
and double-negative (purple) subsets highlighted.
The percentages represent mean ± SD, n = 3–6 for
DC-Notch1D and DC-DNMAML1 and 11–12 for
DC-Notch2D.
(D) The percentage among total splenocytes (top)
and absolute number (bottom) of CD11b+ and
CD8+ DC subsets (mean ± SD of 8–10 animals per
group).
(E) The expression of SIRPa and CD24 in gated
CD11chiMHC II+CD11bCD8 double-negative
DCs from conditional Notch2 (DC-Notch2D) and
littermate control (Ctrl) spleens. The SIRPa+ and
CD24+ populations indicative of the differentia-
tion toward CD11b+ and CD8+ DC subsets,
respectively, are indicated (representative of two
animals).
(F) Expression of surface markers in CD11b+ DCs
from DC-Notch2D and control spleens.
See also Figure S1.
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Notch2 Controls DC Differentiationand GFPlo populations, whereas in DC-RbpjD spleens the GFPlo
population was missing (Figure 2A). To identify a positive marker
of this Notch-dependent DC population, we performed microar-
ray analysis of total CD11b+ DCs from DC-RbpjD spleens and
focused on genes that encode cell surface markers (data not
shown). One prominently reduced gene encoded Esam, an
immunoglobulin superfamily adhesion molecule that is ex-
pressed on endothelium and regulates neutrophil extravasation
(Wegmann et al., 2006). We found that among the splenocytes,
Esam was abundant in a subset of CD11b+ DCs, low in CD8+
DCs, and absent from non-DCs (Figure S2). The combination
of Esam with Cx3cr1-GFP defined two distinct populations,
EsamloGFPhi and EsamhiGFPlo, the latter completely absent in782 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.DC-RbpjD splenocytes (Figure 2B). The
RBPJ-dependent Esamhi population was
also defined by low expression of
Clec12a, a C-type lectin expressed by
CD8+ DCs, pDCs, and myeloid cells (La-
houd et al., 2009). Staining with Esam,
particularly in combination with Clec12a,
resolved the two CD11b+ DC populations
and allowed their analysis in the absence
of Cx3cr1-GFP reporter (Figure 2C). The
Esamhi but not EsamloCD11b+ DCs were
nearly absent in all examined Notchmutants including DC-RbpjD, DC-Notch2D, and DC-DNMAML1
(Figure 2D). In contrast, the low Esam expression on CD8+
DCs was minimally affected by Notch2 loss (Figure S2).
To test the effect of Notch overactivation in DCs, we used the
Itgax-cre strain in conjunction with a Cre-inducible overexpres-
sion cassette encoding Notch1 intracellular domain (NICD) (Buo-
namici et al., 2009). The NICDs of Notch1 and Notch2 are highly
homologous (Radtke et al., 2010) and should be interchange-
able in gain-of-function experiments. In the resulting DC-NICD
animals, splenic CD11b+ DCs consisted almost exclusively of
EsamhiClec12a cells (Figure 2E). Furthermore, the expression
of Esam was increased in all DCs including the CD8+ subset
(Figure 2F), showing Esam as a faithful readout of Notch activity
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Figure 2. Notch2-RBPJ Signaling Specifies a
Distinct Population of CD11b+ DCs
(A) The expression of Cx3cr1-GFP reporter in CD11b+
splenic DCs from conditional RBPJ-deficient (DC-RbpjD)
mice. Shown is the histogram of GFP expression in gated
CD11chiMHC II+CD11b+ DCs from Cx3cr1-GFP+ control
(Ctrl) or DC-RbpjDmice (representative of four animals per
group).
(B) The expression of Esam versus GFP in gated CD11b+
splenic DCs from Cx3cr1-GFP+ control or DC-RbpjDmice.
(C) The expression of Esam versus Clec12a in gated
CD11b+ splenic DCs from DC-RbpjD or control mice.
(D) The percentage among total splenocytes (top)
and absolute number (bottom) of the Esamhi and
EsamloCD11b+ DC subsets in mice with DC-specific tar-
geting of the indicated genes (mean ± SD of three to five
animals). Significance is indicated as in Figure 1.
(E) Splenic DC populations in mice with DC-specific
expression of Notch1 intracellular domain (DC-NICD).
Shown are staining profiles of gated splenic CD11chiMHC
II+ DCs and of their CD11b+ subset from DC-NICD mice or
Cre-negative littermate controls (Ctrl). Representative of
eight animals per genotype.
(F) The expression of Esam in splenic CD11b+ and CD8+
DCs from DC-NICD and control mice.
See also Figure S2.
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Notch2 Controls DC Differentiationin DCs. Altogether, these data suggest that splenic CD11b+ DCs
contain a distinct Esamhi population that is directly regulated by
Notch2-RBPJ signaling.
Genetic and Phenotypic Analysis of Splenic Esamhi DCs
We have tested genetic requirements for the development of
Notch-dependent EsamhiCD11b+ DC population. Splenocytes
from Flt3-deficient mice showed a modest but significant reduc-
tion of Esamhi population (Figures 3A and 3B), suggesting that
Flt3 signaling contributes to its development or homeostasis.
The blockade of lymphotoxin b receptor (LTbR) signaling
partially reduces the number of splenic CD11b+ DCs and impairs
their in situ proliferation in a cell-intrinsic manner (De Trez et al.,
2008; Kabashima et al., 2005). We found that the fraction ofImmunity 35, 780–Esamhi but not of Esamlo DCs was severely
reduced in Ltbr/ mice (Figures 3A and 3B).
To circumvent the pleiotropic defects of
LTbR deficiency, we analyzed competitive
chimeras reconstituted with a mixture of wild-
type and LTbR-deficient BM. The fraction of
LTbR-deficient donor cells was reduced in
Esamhi DC population, suggesting that the
phenotype was at least partially cell intrinsic
(Figures 3C and 3D). In contrast, mice with
DC-specific targeting of Irf4 (Klein et al., 2006),
a transcription factor regulating CD11b+ DC
development, showed marginal decrease of
both Esamhi and Esamlo populations (Figure 3B
and data not shown). Thus, EsamhiCD11b+ DCs
are genetically distinct from Esamlo DCs and
specifically depend on Notch2-RBPJ and
LTbR signaling and to a lesser extent on Flt3
signaling.Cell surface staining of CD11b+ DCs showed that the Esamhi
Cx3cr1-GFPlo population was uniformly positive for CD4 and
Dcir2 (Figure 4A), in agreement with the preferential loss of
CD4+ and Dcir2+ DCs after Notch2 deletion (Figure 1F).
Conversely, EsamloCx3cr1-GFPhi cells were heterogeneous for
CD4 and Dcir2 and high for CD11b andClec12a. Esamlo cells ex-
pressed high amounts of Flt3 and LTbR, despite their indepen-
dence of these receptors (Figures 4A and 4B; Figure S3). Cyto-
spin preparations of sorted Esamhi DCs revealed irregular
nuclei and thin cytoplasmic veils, whereas Esamlo DCs showed
typical mononuclear morphology (Figure 4C). Notably, Esamlo
DCs appeared distinct from splenic macrophages (Figure 4C)
or intestinal CD11b+CD103 DCs (Bogunovic et al., 2009),
because they did not contain prominent cytoplasmic vesicles.791, November 23, 2011 ª2011 Elsevier Inc. 783
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Figure 3. The Development of EsamhiCD11b+ DCs Requires LTbR
Signaling
(A) Splenic CD11b+Esamhi DC subset in experimental (Expt) Flt3/ or Ltbr/
animals or respective wild-type controls (Ctrl). The DC-RbpjD splenocytes that
lack Esamhi DCs (Figure 2D) are included for comparison. Shown are staining
profiles of gated B220CD11b+CD8 splenocytes, with the CD11chiEsamhi
DC population highlighted.
(B) The fraction of Esamhi and Esamlo DC subsets among total splenocytes
from Flt3/, Ltbr/, or DC-Irf4D experimental (Expt) animals or controls (Ctrl).
Significance is indicated as in Figure 1 (mean ± SD of four to five animals).
(C) Splenic CD11b+Esamhi DC population among gated wild-type competitor
(WT) or Ltbr/ donor populations in competitively reconstituted BM chimeras,
shown as in (A) (mean ± SD of three animals).
(D) The fraction of WT competitor- or Ltbr/ donor-derived CD11b+ DC
subsets among total splenocytes in the BM chimeras (mean ± SD of three
animals).
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Notch2 Controls DC DifferentiationAfter in vivo pulse with nucleoside analog 5-bromo-20-deoxyuri-
dine (BrdU), EsamhiCD11b+ DC incorporated more BrdU than
Esamlo DCs (Figure 4D), revealing a faster turnover. Although
the contribution of progenitors cannot be ruled out, the short784 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.BrdU pulse revealed more proliferating cells among Esamhi
DCs (Figure 4E). Altogether, the Esamhi subset of CD11b+ DCs
appears distinct in its higher turnover rate and dependence on
Notch2 and LTbR signaling.
Gene Expression Profiles of Splenic CD11b+ DC
Populations
To confirm genetic differences between the two subsets of
CD11b+ DCs, we compared genome-wide expression profiles
of wild-type Esamhi and EsamloCD11b+ DC populations, along
with CD11b+ DCs from DC-RbpjD mice. No major differences
in the expression of Notch2 or other pathway components
were found bymicroarray or quantitative polymerase chain reac-
tion (PCR) (qPCR) (Figure S3), suggesting control by other
factors such as ligand availability. Clustering analysis confirmed
that RBPJ-deficient DCs were very similar to the Esamlo subset
(Figure 5A), as suggested by surface phenotype (Figure 2). Pair-
wise comparison of Esamhi and Esamlo populations (Figure 5B;
Table S1) showed the expected differential expression of Esam
and Clec12a. One of the most differentially expressed genes
was Gpr4, which encodes a G protein-coupled receptor and is
preferentially expressed in CD11chi cDCs as revealed by a
Gpr4 locus-driven transgenic GFP reporter (Figure S3). This
reporter confirmed the expression of Gpr4 in Esamhi but not
Esamlo DCs (Figure S3). Finally, Esamhi DCs showed lower
expression of cell cycle inhibitor Cdkn1a (p21), in accordance
with their higher proliferation rate.
Next, the Immgen database (Heng and Painter, 2008) was
used to derive expression signatures of splenic CD11b+CD4+
and CD11bCD8+ DCs and of blood Ly6C+MHC II+ monocytes.
We then examined the distribution of these signature gene sets
among Esamhi and EsamloCD11b+ DC populations. As shown
in Figure 5C, genes characteristic of all DCs were equally
expressed by both populations, confirming that they represent
bona fide DCs. In contrast, CD11b+ DC-specific genes including
the Notch target Dtx1 were preferentially expressed in the
Esamhi subset. Conversely, monocyte-specific genes were pref-
erentially expressed in Esamlo cells, including such canonical
myeloid genes as Ly6c, cytokine (Csf1r, Csf3r) and chemokine
(Ccr2) receptors, and lysozyme (Lyz1, Lyz2). Notably, the expres-
sion of myeloid genes such as colony stimulating factor (CSF)
receptors in Esamlo DCs appear significantly lower than in
macrophages (Figure S3). Thus, the Esamhi population features
the unique expression profile of CD11b+ DCs, whereas Esamlo
population appears closer to but distinct from monocytes or
macrophages.
By using red fluorescent protein (RFP) reporter driven by Ccr2
locus (Saederup et al., 2010), we found that Esamhi DCswere the
only splenic DC population with low RFP expression, while
Esamlo DCs and the majority of CD8+ DCs were Ccr2-RFPhi
(Figure 5D). To confirm the differential relationship of Esamhi
and Esamlo DCs to myeloid cells, we used lineage tracing with
a myeloid-specific Lyz2-cre (also known as LysM-cre) deleter
strain (Jakubzick et al., 2008; Liu et al., 2009). In Lyz2-cre mice
crossed to a cre-inducible yellow fluorescent protein (YFP)
reporter, splenic Esamhi DCs as well as CD8+ DCs harbored
only a small (5%–7%) fraction of recombined YFP+ cells (Fig-
ure 5E). In contrast, the Esamlo DCs showed substantial recom-
bination (30%) that was nevertheless lower than in monocytes
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Figure 4. Phenotypic Analysis of the Splenic
CD11b+ DC Subsets
Unless indicated otherwise, Cx3cr1-GFP reporter mice
were used to separate the EsamhiGFPlo and EsamloGFPhi
subsets of CD11chiCD11b+CD8 splenic DCs.
(A) Expression of the indicated surface markers in the
gated EsamhiGFPlo and EsamloGFPhi subsets. Dashed
lines indicate positive staining threshold.
(B) Expression of LTbR on the indicated DC subsets from
wild-type mice.
(C) Microphotographs of the sorted DC subsets stained
by Giemsa stain on cytospin preparations. The CD11c
CD11b+F4/80+ Cx3cr1-GFP+ macrophages (MF) are
shown for comparison (magnification, 4003).
(D) Histograms of BrdU staining in the gated DC subsets
after 2 days of in vivo BrdU pulse. The percentages of
BrdU+ cells are indicated; representative of four animals.
(E) Cell cycle profiles of DC subsets after 2 hr of in vivo
BrdU pulse. Shown are gated DC subsets stained for DNA
content (DAPI) and BrdU incorporation; the fractions of
cells in S andG2/M phases are indicated (representative of
two animals).
See also Figure S3.
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DCs are uniquely low for Ccr2, have no developmental history
of Lyz2 expression, and therefore are not derived from the
Esamlo population or from monocytes.
The differences in signaling requirements, gene expression
profile, and Lyz2 expression history suggest that the Esamhi
and Esamlo population may arise from different precursors.
Indeed, adoptively transferred Cx3cr1-GFP+ MDPs gave rise to
both GFPhi and GFPlo splenic CD11b+ DC populations, whereas
CDPs gave rise almost exclusively to GFPloCD11b+ DCs corre-
sponding to the Esamhi subset (Figure S3). These data suggest
that the GFPloEsamhi subset represents the canonical CDP-
derived splenic DC population; conversely, GFPhi DCs probably
arise from different myeloid progenitors.
Functional Analysis of Splenic CD11b+ DC Populations
The Esamlo DC subset showed preferential expression of
multiple genes associated with TLR-mediated pathogen
sensing, including several TLRs, MyD88, CD14, and CD36 (Fig-Immunity 35, 780–ure 6A; Table S1). The expression of these
genes in Esamlo DCs was nevertheless lower
than in macrophages (Figure 6B). We therefore
tested the ability of CD11b+ DC subsets
to produce cytokines in response to TLR
ligands. Esamlo DCs efficiently produced tumor
necrosis factor alpha (TNF-a) and IL-12 in
response to the TLR9 agonist CpG DNA, in
contrast to the weak production by Esamhi
DCs (Figure 6C). CD11cCD11b+ monocytes
and macrophages produced more TNF-a but
less IL-12 than Esamlo DCs, underscoring the
distinct functionality of the latter population. A
similarly superior cytokine production by Esamlo
over Esamhi DCs was observed in response to
TLR2 agonist heat-killed L. monocytogenes
(Figure 6D) and TLR7 agonist gardiquimod(data not shown). No expression of interferon-b or interleukin-
10 by either DC population could be detected under these condi-
tions (data not shown). Furthermore, Esamlo DCs showed
stronger TLR-mediated induction of costimulatory molecules
than Esamhi DCs (Figure 6E), suggesting a higher overall sensi-
tivity to TLR ligands.
Both subsets of CD11b+ DCs showed efficient phagocytosis
of in vivo injected polystyrene beads (Figure S4). In an in vitro
Ag presentation assay, both Esamlo and Esamhi DCs sorted
from ovalbumin (OVA)-pulsed mice efficiently primed naive
OVA-specific CD4+ OT-II T cells (Figure S4). Furthermore,
splenic DCs from DC-RbpjD mice elicited strong OVA-specific
OT-II proliferation in vitro, despite the lack of Esamhi DC subset.
These data suggest that Esamhi and Esamlo DCs are equally
capable of Ag-specific T cell priming in vitro on a per cell basis.
To test the role of Esamhi DCs in T cell priming in vivo, we adop-
tively transferred carboxyfluorescein diacetate succinimidyl
ester (CFSE)-labeled OT-II T cells into DC-RbpjDmice and immu-
nized with OVA. Three days after immunization, OT-II T cells791, November 23, 2011 ª2011 Elsevier Inc. 785
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Figure 5. Gene Expression Profiles of Splenic
CD11b+ DC Subsets
(A) The comparison of control and RBPJ-deficient CD11b+
DCs. Splenic CD11b+ DCs from Cx3cr1-GFP+ DC-RbpjD
mice were sorted along with the EsamhiGFPlo and Esamlo
GFPhi subsets of CD11b+ splenic DCs from control
Cx3cr1-GFP+ mice. Shown is unsupervised clustering
analysis of the resulting microarray expression profiles.
(B) Pairwise comparison of the Esamhi and Esamlo
subsets. The probes overexpressed >2-fold in the
respective populations are shown in green and red, and
their percentage among the total probes is indicated.
Probes for select relevant genes are highlighted in blue.
(C) The expression of signature probe sets in the Esamhi
and Esamlo subsets. The signature sets of total DCs,
CD11b+ DCs and monocytes were derived from Immgen
database and their distribution among the Esamhi and
Esamlo subsets is depicted as in (B).
(D) The expression of Ccr2-RFP reporter in DC subsets.
Shown are histograms of RFP expression in the indicated
splenic populations including CD11cCD11b+ monocytes
and macrophages (Mo-MF), and Clec12a and Clec12a+
CD11b+ DCs corresponding to Esamhi and Esamlo
subsets, respectively.
(E) Efficiency of Lyz2-cre recombination in DC subsets.
Shown are histograms of YFP expression in the indicated
splenic populations of Lyz2-cre+ mice with cre-inducible
YFP reporter allele.
See also Table S1.
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Notch2 Controls DC Differentiationshowed extensive proliferation (as measured by CFSE dye
dilution) in the spleens of control mice, but only minor prolifera-
tion in the spleens of DC-RbpjD mice (Figure 6F). Because DC-
RbpjD spleens specifically lack Esamhi DCs, we conclude that
this subset is required for optimal T cell priming in the spleen
in vivo.786 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.Notch2 Is Required for the Development
of Intestinal CD11b+CD103+ DCs
Given the tissue-specific nature of Notch
signaling, we examined the role of Notch2 in
DC differentiation outside of the spleen. We
found that DC-Notch2D mice had normal
numbers of CD11b+ andCD103+ DCs and Lang-
erhans cells in the skin and/or skin-draining LN
(Figure S5). Similarly, CD11b+ and CD103+ DCs
in the lung and liver were unaffected by Notch2
deletion (Figure S5). However, analysis of DCs
in the intestinal LP revealed selective depletion
of the CD11b+CD103+ subset (Figures 7A and
7B). In contrast, the monocyte-derived CD11b+-
CD103populationwasunaffected,whereas the
CD103+ population was moderately increased.
Similarly, the fraction of CD11b+CD103+ DCs
migrating from the LP was selectively reduced
in the mesenteric LN (Figure 7C). The LP
CD11b+CD103+ DCs did not express Esam or
Dtx1 and were not reduced in DC-RBPJD or
DC-DNMAML1mice (data not shown), suggest-
ing that the Notch2 signal is transient or qualita-
tively different in this subset. However, the ex-
pression of the Gpr4 reporter was detected inCD11b+CD103+ but not in CD11b+CD103 DCs (Figure S3). This
selective expression was similar to Gpr4 expression in Esamhi
but not Esamlo splenic DCs, illustrating the similarity between
Notch2-dependent DC subsets in the spleen and intestine.
To test the functional consequences of CD11b+CD103+
DC depletion, we examined intestinal T cell populations in
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Figure 6. Functional Properties of Splenic CD11b+ DC Subsets
(A) The expression of indicated genes in GFPloEsamhi andGFPhiEsamlo subsets of splenic CD11b+DCs sorted fromCx3cr1-GFPmice. Data represent normalized
expression values relative to the Esamhi sample as determined by qPCR (mean ± SD of triplicate reactions).
(B) The expression of indicated genes in the same DC subsets as well as in CD11cCD11b+F4/80+GFP+ macrophages (MF), determined by qPCR as in (A) and
shown on a log scale.
(C) Cytokine production by CD11b+ DCs in response to TLR9 ligand CpG. Lymphocyte-depleted splenocytes fromCx3cr1-GFPmice were incubated for 6 hr with
CpG and stained for surface markers and intracellular TNF-a or IL-12. Shown are cytokine expression profiles in GFPloEsamhi or GFPhiEsamlo subsets of
CD11chiCD11b+ DCs or in CD11cCD11b+GFPhi monocytes and macrophages (Mo-MF). Data are representative of three independent experiments.
(D) TNF-a production by CD11b+ DCs in response to TLR ligands. Splenocytes from Cx3cr1-GFP mice were activated with CpG or TLR2 ligand heat-killed
L. monocytogenes (HKLM) and stained as above.
(E) Phenotypic maturation of CD11b+ DCs in vitro. Splenocytes from Cx3cr1-GFP mice were activated with CpG or HKLM and stained for DC markers as above.
Shown are staining profiles of CD11b+ DC subsets for CD40, with mean fluorescence intensities indicated.
(F) In vivo CD4+ T cell priming in the absence of Esamhi DCs. DC-RbpjD or littermate control (Ctrl) mice were administered CFSE-labeled OVA-specific OT-II T cells
and immunized with OVA. Shown are CFSE staining profiles of gated OT-II T cells from the recipient spleens 3 days after immunization. The fractions of T cells that
did not divide or divided 1–3 and >3 times are indicated (mean of two recipients).
See also Figure S4.
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Notch2 Controls DC DifferentiationDC-Notch2D mice. Whereas the fraction of regulatory CD4+ T
(Treg) cells expressing transcription factor FoxP3 was un-
changed, the IL-17-producing Th17 cells were reduced 50%I(Figure 7D). Similar results were observed in the small intestine
(Figure 7D) and colon (not shown). Thus, Notch2 provides a
tissue-specific differentiation signal for the CD11b+CD103+mmunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc. 787
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Figure 7. Notch2 Controls the Development of Intestinal CD11b+CD103+ DCs
(A) DC populations in the intestinal lamina propria from DC-Notch2Dmice and littermate controls. Shown are staining profiles of CD45+CD11chiMHC II+ DCs and
of the gated CD11b+ DCs, highlighting the CD11b+CD103+ DC subset. Fractions represent average ± SD of four animals per group. Statistical significance is
indicated as in Figure 1.
(B) Absolute numbers of the indicated DC subsets (mean ± SD of four animals).
(C) Staining profiles of CD11chiMHC II+ DCs from the mesenteric lymph nodes. Fractions represent average ± SD of seven animals per group.
(D) Effector T cell populations in the intestine. Lymphocytes were isolated from the LP of small intestine and stained ex vivo for intracellular FoxP3 or activated
in vitro with PMA plus ionomycin and stained for intracellular IL-17. Shown are profiles of CD11chiMHC II+ LP DCs and of gated TCRb+CD4+ T cells isolated
ex vivo or activated in vitro (two pairs of littermates shown; representative of four DC-Notch2D animals).
See also Figure S5.
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Notch2 Controls DC DifferentiationDC population, which in turn support optimal effector T cell
differentiation in the intestine.
DISCUSSION
Although Notch signaling has been indirectly implicated in
various aspects of DC development or function (Caton et al.,
2007; Cheng et al., 2003; Feng et al., 2010; Zhou et al., 2009),
the specific Notch receptor involved and DC populations
affected were unclear. Here we have demonstrated that Notch2
receptor controls the development of specific DC subsets in the
spleen and intestine. In contrast, Notch1was dispensable for DC
development, consistent with previous results of global inducible
Notch1 deletion (Radtke et al., 2000). Similarly, Notch4 defi-
ciency did not affect DC populations (data not shown), establish-
ing Notch2 as a nonredundant Notch receptor regulating the DC
lineage development.788 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.Canonical Notch signaling occurs through the NICD-RBPJ-
MAML transcriptional activation complex, and Rbpj deletion
(Han et al., 2002) or DNMAML1-mediated complex disruption
(Maillard et al., 2004) recapitulates Notch receptor deletion in
lymphocytes. Indeed, CD11b+ splenic DCs were equally
affected by the loss of Notch2 or RBPJ or by DNMAML expres-
sion. However, Notch2 deletion impaired the development of
splenic CD8+ DCs and intestinal CD11b+CD103+ DCs, whereas
Rbpj deletion spared both subsets (Caton et al., 2007; data not
shown). Although Notch2 signaling in these DC subsets may
include a noncanonical RBPJ-independent pathway, this dis-
crepancy probably reflects technical aspects of gene targeting
in DCs. Because DCs have a rapid turnover and Itgax-cre
recombination commences after DC commitment, delayed
recombination kinetics and/or increased protein perdurance of
RBPJ versus Notch2 would mitigate the phenotype. Indeed,
continuous global deletion of RBPJ caused apparent loss of
Immunity
Notch2 Controls DC DifferentiationCD8+ DCs (Feng et al., 2010), suggesting the predominant role of
canonical Notch2 signaling in DC development.
Notch signaling can provide the initial commitment signal as
well as sustain further differentiation steps and/or homeostasis
of a given cell type (Radtke et al., 2010; Yashiro-Ohtani et al.,
2010). In splenic DCs,Notch2 deletion affected both DC subsets
and caused accumulation of immature CD11bCD8 cells. In
addition, mature CD11b+ DCs demonstrate ongoing Notch
signaling activity, as evidenced by RBPJ-dependent expression
ofDtx1 and sensitivity to Notch2-RBPJ loss or DNMAML1 induc-
tion. In contrast, CD8+ DCs do not express Dtx1 and are less
affected by Rbpj deletion or DNMAML1 induction. Thus, Notch2
signaling appears to initiate and maintain the differentiation of
splenic CD11b+ DC subset, starting at the common pre-DC
stage and thereby promoting CD8+ DC development as well. In
tissues such as the intestine, Notch signaling in CD11b+CD103+
DCsmay commence after the pre-DC stage andwould not affect
CD103+ DCs.
Our data illustrate a tissue-specific role of Notch signaling in
DC differentiation in the spleen and intestinal LP, in contrast to
its proposed general role in DC development (Cheng et al.,
2003; Zhou et al., 2009). Indeed, both tissues are classical sites
of Notch activity, which drives the respective differentiation of
splenic MZ B cells and of the intestinal epithelium (Wilson and
Radtke, 2006). MZ B cell development is mediated solely by
Notch ligand Dll1 (Hozumi et al., 2004), whereas the latter
involves both Dll1 and Dll4 (Pellegrinet et al., 2011). Because
both Dll1 and Dll4 are also expressed in the splenic red pulp
and MZ (Tan et al., 2009), these two ligands may redundantly
regulate Notch2-mediated DC development both in the spleen
and intestine. A notable molecular feature of the splenic MZ is
active LTbR signaling, which is required both for MZ formation
and MZ B cell maintenance, probably in a cell-extrinsic manner
(Mebius and Kraal, 2005). We found that both Notch2 and
LTbR signals control the development of CD11b+ splenic DCs.
The contribution of LTbR was at least in part intrinsic to the
hematopoietic compartment, consistent with previous studies
on LTbR in DC development (Kabashima et al., 2005) and func-
tion (Summers deLuca et al., 2011). Our results establish these
two pathways as common regulators of the splenic MZ and
of its two major immune constituents, the MZ B cells and
CD11b+ DCs.
The CD11b+ and CD8+ DC populations in the lymphoid organs
of naive animals were thought to be genetically and functionally
homogeneous. However, it has been demonstrated recently
that CD8+ DCs are comprised of two distinct populations, the
Cx3cr1-GFP classical CD8+ DCs and Cx3cr1-GFPhi cells
affiliated with the pDC lineage (Bar-On et al., 2010). Here we
combined genetic analysis with the Cx3cr1-GFP reporter and
surface marker Esam to similarly subdivide the splenic CD11b+
DCs. In particular, we found that Notch or LTbR signaling
blockade causes a complete ablation of the Esamhi DC subset,
rather than a partial decrease of all splenic CD11b+ DCs. The
Notch2-dependent Esamhi population exhibited properties of
classical DCs, including cytoplasmic ‘‘veils’’ and rapid turnover.
Although the CD4+ subset of CD11b+ DCswas reported to incor-
porate BrdU at a slower rate (Kamath et al., 2000), Esam is
expressed only in a fraction of CD4+ DCs and thus provides
a more precise subset definition. Furthermore, the higher turn-Iover of RBPJ-deficient CD11b+ DCs (Caton et al., 2007) was
based on prolonged BrdU pulse that aggregated proliferation
with cell death andmigration. Most importantly, the higher prolif-
eration rate of Esamhi DCs is consistent with their dependence
on Flt3 and LTbR signaling, both of which promote DC prolifera-
tion in situ (Kabashima et al., 2005; Waskow et al., 2008).
All blood-derived DCs in lymphoid organs are thought to
originate from CDPs in the BM via the committed pre-DCs
entering from the blood and differentiating in situ. Indeed, the
EsamhiCx3cr1loCD11b+ splenic DCs apparently arise in this
pathway because they can be derived from CDPs and lack
developmental history of myeloid-specific Lyz2 gene expres-
sion. In contrast, the EsamloCx3cr1hi subset could not be derived
from transferred CDPs and preferentially expressed myeloid
genes, although at much lower level than monocytes or macro-
phages. Because splenic DCs cannot be derived from mono-
cytes (Varol et al., 2007), the Esamlo DCs probably arise from
earlier progenitors such as MDPs. Splenic DC development is
not dependent on myeloid cytokine receptors Csf1r (Ginhoux
et al., 2009) or Csf2r (our unpublished data), consistent with
the lower expression of these genes in Esamlo DCs relative to
macrophages (Figure S3). In any case, our results suggest that
the spleen is similar to nonlymphoid organs in the dual origin of
its resident DCs from the CDPs and from a parallel myelomono-
cytic pathway.
In the spleen, the absence of Esamhi DCs after DC-specific
Rbpj deletion impaired CD4+ T cell priming. This was not
because of higher Ag uptake or presentation capacity of Esamhi
DCs on a per cell basis; therefore, Esamhi DCs may be uniquely
suited for T cell priming because of their specific localization in
the MZ and/or migration properties. In the intestinal LP, the
CD11b+CD103+ cells represent a unique DC population that
migrates to the mesenteric LN in the steady state and upon
inflammation, suggesting its likely role in T cell priming (Bogu-
novic et al., 2009). We found that the loss of this population after
DC-specific Notch2 targeting was associated with a reduced
fraction of Th17 cells, a major effector CD4+ T cell population
in the intestine. Although this finding remains to be confirmed
in mice with pure genetic background and more defined micro-
flora, it is consistent with the recently reported capacity of
CD11b+CD103+ DCs to induce Th17 cell differentiation in vitro
(Denning et al., 2011). Thus, DC-specific Notch2 targeting
provided the first insight into the specific function of CD11b+
CD103+ DC subset in vivo, opening the way for future studies
of immune responses and tolerance in the intestine. Collectively,
our results establish Notch2 as a common regulator of the two
key T cell-priming DC populations in the spleen and the intestine.EXPERIMENTAL PROCEDURES
Animals
The Itgax-cre hemizygous transgene was used to generate the following
experimental animals on C57BL/6 (B6) background unless indicated other-
wise: DC-RbpjD (Rbpjflox/flox), DC-Notch1D (Notch1flox/flox), DC-Notch2D
(Notch2flox/flox, mixed B6/129), DC-Irf4D (Irf4flox/flox), DC-DNMAML1 (Rosa26-
StopFlox-DNMAML1, B6 or B6129F1), and DC-NICD (Eef1a1-StopFlox-
NICD1, mixed B6/129). Where indicated, DC-RbpjDmice carried heterozygous
Cx3cr1-GFP reporter allele. Because the Itgax-cre transgene does not affect
DC numbers or phenotype (Caton et al., 2007), Cre-negative littermates
were used as controls for the respective Itgax-cre+ animals. For the analysismmunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc. 789
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Notch2 Controls DC Differentiationof intestinal T cells, cohoused sex-matched littermates were used. Germline
null mutants of Flt3 and LTbR on B6 background, as well as competitive
chimeras established from LTbR-null BM have been described (Summers
deLuca et al., 2011; Waskow et al., 2008). Chimeras were analyzed 11 weeks
after reconstitution and the donor- or competitor-derived cells were distin-
guished by differential CD45 isoform expression. Homo- or heterozygous
Cx3cr1-GFP and heterozygous Ccr2-RFP reporter mice were on the B6 back-
ground. The Lyz2-cre lineage tracing was performed as described (Jakubzick
et al., 2008) and utilized mice hemizygous for Lyz2-cre and heterozygous for
Rosa26-StopFlox-EYFP. All animal studies were performed according to the
investigator’s protocol approved by the Institutional Animal Care and Use
Committee of Columbia University.
Cell Analysis
Cells were isolated ex vivo from lymphoid organs and stained for cell surface
markers as described (Caton et al., 2007; Liu et al., 2009). The antibodies used
for staining are listed in Supplemental Experimental Procedures. The isolation
and analysis of DCs from the intestinal LP and other tissues was done as in
Bogunovic et al. (2009) and Ginhoux et al. (2009). The isolation and analysis
of intestinal T cells was done as described (Ivanov et al., 2006). Fluorochrome-
or biotin-conjugated antibodies were from eBioscience or BD Biosciences.
Biotinylated anti-Clec12a was kindly provided by M. Lahoud at the Walter
and Eliza Hall Institute. The samples were acquired on a LSR II flow cytometer
or sorted on FACSAria flow sorter (BD Immunocytometry Systems) and
analyzed with FlowJo software (Treestar Inc.). Cytospin preparations were
done onCytospin 3 centrifuge (Thermo Shandon) and stained byGiemsa stain.
For BrdU incorporation, Cx3cr1-GFP reporter mice were either injected i.p.
with 1.5 mg BrdU and analyzed 2 hr later or injected with 1.5 mg BrdU for 2
consecutive days and analyzed 48 hr after the first injection. BrdU staining
was performed with APC BrdU Flow Kit (BD Biosciences) and combined
with DAPI staining for 2 hr pulse. To measure cytokine production, spleno-
cytes from Cx3cr1-GFP mice were depleted of lymphoid and erythroid
cells by negative selection on MACS columns (Miltenyi). The DC-enriched
flow-through fraction was incubated in serum-containing medium at
37C with 100 nM CpG-B oligonucleotides (ODN1826) or 108 heat-killed
L. monocytogenes (Invivogen). After 2 hr, Brefeldin A (10 mg/ml) was added
and the cells were incubated for an additional 4 hr. Cells were stained for
surface markers, fixed, permeabilized, and stained with APC-conjugated anti-
bodies to IL-12 or TNF-a (BD Biosciences) according to the manufacturer’s
instructions.
Gene Expression Analysis
For microarray analysis, spleens from Cx3cr1-GFP+ DC-RbpjD mice or Cre-
negative littermate controls were isolated and depleted of lymphoid and
erythroid cells by negative selection onMACS columns. Total CD11chiCD11b+
DCs from DC-RbpjD spleens (uniformly EsamloGFPhi, see Figure 2) or Esamlo
GFPhi and EsamhiGFPlo subsets thereof from control mice were sorted and
total RNA was isolated with RNeasy columns (QIAGEN). Precipitated RNA
was reverse-transcribed, labeled, and hybridized to GeneChip Mouse Gene
1.0 ST Array (Affymetrix) according to the manufacturer’s instructions.
RMA-normalized gene expression values were analyzed with NIA Array soft-
ware (Sharov et al., 2005). The signatures of normal DC populations were
derived by clustering analysis of Immgen subsets DC.4+.Sp, DC.8+.Sp, and
Mo.6c+II+.Bl (Heng and Painter, 2008) and are available from the authors
upon request. Real-time qPCR was performed as described (Caton et al.,
2007).
T Cell Proliferation Assay
Splenic and LN CD4+ T cells from OVA-specific OT-II transgenic mice (Barn-
den et al., 1998) were enriched by negative selection with MACS columns,
labeled with CFSE, and injected intravenously (i.v.) (2 3 106 per animal) into
DC-RbpjD or control mice. After 24 hr, recipient mice received 10 mg OVA
(Sigma) i.v. and were analyzed 72 hr later. Transferred T cells were identified
as CD4+ TCR Va2+ TCR Vb5+.
Statistical Analysis
Statistical significance was estimated with unpaired, two-tailed Student’s
t test.790 Immunity 35, 780–791, November 23, 2011 ª2011 Elsevier Inc.ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE31551.
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